Saroja Pharma Ind Key Ratios
NSE: SAROJA
₹38.95
₹0.00 (0.00%)As on 07-Sep-2026 11:26IST
Market cap
₹16 Cr
Revenue (TTM)
₹54 Cr
P/E Ratio
9.7
P/B Ratio
1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | 32.11 | -1.16 | -- |
| EBIT | -- | -- | 8.52 | 9.13 | -- |
| Net Profit | -- | -- | 17.75 | -3.20 | -- |
| EPS | -- | -- | 17.75 | -12.83 | -- |
| Book Value | -- | -- | 7.06 | 41.66 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Mar-25 | Mar-24 | Mar-23 |
| EBIT-Margin
| 5.44 | -- | 4.98 | 6.06 | 5.29 |
| Net Margin
| 2.06 | -- | 1.92 | 2.15 | 2.11 |
| Return on equity
| 13.00 | -- | 6.82 | 8.90 | 23.28 |
| Return on Capital
| 16.52 | -- | 12.56 | 14.91 | 22.10 |
| Return on Assets
| 4.18 | -- | 3.13 | 3.67 | 5.76 |
| Debt to Equity (x)
| -- | -- | 0.60 | 0.39 | 2.00 |
Profitability
ROCE
12.56
Higher than Peers by 3.41
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
12.56
|
14.91
|
22.10
|
33.73
|
34.59
|
|
Peer Median
|
9.15
|
9.86
|
10.38
|
10.23
|
--
|
ROE
6.82
Higher than Peers by 0.83
Profit after tax / Average Net worth * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
6.82
|
8.90
|
23.28
|
45.95
|
78.14
|
|
Peer Median
|
5.99
|
5.33
|
7.17
|
8.79
|
--
|
ROA
3.13
Lower than Peers by 0.54
Profit after tax / Average Total assets * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
3.13
|
3.67
|
5.76
|
9.61
|
8.89
|
|
Peer Median
|
3.67
|
4.83
|
5.33
|
5.27
|
--
|
EBIT Margin
4.98
Higher than Peers by 3.40
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
4.98
|
6.06
|
5.29
|
3.70
|
3.50
|
|
Peer Median
|
1.57
|
-0.69
|
-7.53
|
2.93
|
--
|
Net Margin
1.92
Lower than Peers by 5.34
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
1.92
|
2.15
|
2.11
|
2.04
|
1.99
|
|
Peer Median
|
7.26
|
3.51
|
5.34
|
12.65
|
--
|
Cash Profit Margin
2.14
Higher than Peers by 2.14
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
2.14
|
2.39
|
2.25
|
2.13
|
2.06
|
|
Peer Median
|
0.00
|
0.00
|
0.00
|
0.00
|
--
|
Revenue Growth
32.11
Lower than Peers by 26.92
Year on year growth in net sales
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
32.11
|
-18.97
|
-9.78
|
51.75
|
--
|
|
Peer Median
|
59.03
|
23.78
|
185.48
|
46.17
|
--
|
EBIT Growth
8.52
Higher than Peers by 7.81
Year on year growth in operating profit (EBIT)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
8.52
|
-7.14
|
28.98
|
60.42
|
--
|
|
Peer Median
|
0.71
|
-39.89
|
5.86
|
78.09
|
--
|
Net Profit Growth
17.75
Higher than Peers by 15.51
Year on year growth in profit after tax
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
17.75
|
-17.19
|
-6.97
|
55.90
|
--
|
|
Peer Median
|
2.24
|
-1.56
|
-29.54
|
254.00
|
--
|
EPS Growth
17.75
Higher than Peers by 1.76
Year on year growth in earnings per share
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
17.75
|
-39.53
|
-6.98
|
-93.10
|
--
|
|
Peer Median
|
15.99
|
20.00
|
-25.00
|
254.20
|
--
|
Book Value Growth
7.06
--
Year on year growth in book value per share
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
7.06
|
187.84
|
26.34
|
330.17
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.60
Higher than Peers by 0.60
Total debt / Net worth
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
0.60
|
0.39
|
2.00
|
1.52
|
3.22
|
|
Peer Median
|
0.00
|
0.00
|
0.08
|
0.08
|
--
|
Short term debt to equity ratio
0.52
--
(Short term borrowings / Net worth)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
0.52
|
0.21
|
1.45
|
1.10
|
1.71
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.21
Lower than Peers by 0.76
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
1.21
|
1.89
|
1.20
|
1.54
|
1.38
|
|
Peer Median
|
1.97
|
2.54
|
2.22
|
2.59
|
--
|
Quick Ratio
1.21
Lower than Peers by 1.18
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
1.21
|
1.85
|
0.91
|
1.49
|
1.27
|
|
Peer Median
|
2.38
|
3.33
|
2.05
|
2.50
|
--
|
Interest Coverage
2.03
Lower than Peers by 6.04
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
2.03
|
1.83
|
2.13
|
2.97
|
4.12
|
|
Peer Median
|
8.07
|
18.49
|
8.15
|
14.12
|
--
|
Operating Efficiency
Debtors to sales
49.47
Higher than Peers by 29.77
Debtors outstanding / Net Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
49.47
|
39.93
|
22.13
|
25.13
|
19.70
|
|
Peer Median
|
19.70
|
17.80
|
21.35
|
28.80
|
--
|
Asset Turnover
1.63
Lower than Peers by 0.24
Sales / Average Total Assets
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
1.63
|
1.70
|
2.72
|
4.69
|
4.46
|
|
Peer Median
|
1.87
|
0.60
|
0.25
|
0.35
|
--
|
Receivable days
145.45
--
Average Debtors / Sales * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
145.45
|
122.72
|
91.22
|
69.56
|
71.92
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
1.69
--
Average Inventory / Sales * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
1.69
|
19.13
|
15.75
|
3.68
|
6.53
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
74.63
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
74.63
|
61.58
|
45.99
|
35.58
|
47.31
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
72.51
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
72.51
|
80.28
|
60.98
|
37.66
|
31.14
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
14.68
Lower than Peers by 11.19
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
14.68
|
16.07
|
--
|
--
|
--
|
|
Peer Median
|
25.87
|
30.13
|
23.66
|
18.60
|
--
|
Price / Book Value
0.97
Lower than Peers by 0.88
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
0.97
|
0.96
|
--
|
--
|
--
|
|
Peer Median
|
1.84
|
1.22
|
0.81
|
1.08
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
0.43
|
0.69
|
0.53
|
--
|
EV/EBITDA
8.17
Higher than Peers by 32.67
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
8.17
|
7.10
|
4.43
|
2.51
|
2.18
|
|
Peer Median
|
-24.50
|
-39.62
|
-10.36
|
-15.25
|
--
|
Market Cap
15
Lower than Peers by 145
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Saroja Pharma Ind
|
15
|
14
|
--
|
--
|
--
|
|
Peer Median
|
160
|
199
|
362
|
225
|
--
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
